463 related articles for article (PubMed ID: 24746010)
1. Rivaroxaban in acute coronary syndromes--is it prime time?
Asrar ul Haq M; van Gaal WJ
Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
[TBL] [Abstract][Full Text] [Related]
2. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
3. Novel oral anticoagulants in acute coronary syndrome.
Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
[TBL] [Abstract][Full Text] [Related]
4. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
Krantz MJ; Kaul S
J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban for the treatment of acute coronary syndromes.
Wong CK; White HD
Expert Opin Pharmacother; 2013 May; 14(7):917-27. PubMed ID: 23544968
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
Mega JL; Braunwald E; Murphy SA; Plotnikov AN; Burton P; Kiss RG; Parkhomenko A; Tendera M; Widimsky P; Gibson CM
J Am Coll Cardiol; 2013 May; 61(18):1853-9. PubMed ID: 23500262
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban (Xarelto) for acute coronary syndrome.
Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):97. PubMed ID: 22173426
[TBL] [Abstract][Full Text] [Related]
9. Potential role of rivaroxaban in patients with acute coronary syndrome.
Fitchett DH
Drug Des Devel Ther; 2012; 6():349-57. PubMed ID: 23209364
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
[TBL] [Abstract][Full Text] [Related]
11. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
Gibson CM; Chakrabarti AK; Mega J; Bode C; Bassand JP; Verheugt FW; Bhatt DL; Goto S; Cohen M; Mohanavelu S; Burton P; Stone G; Braunwald E;
J Am Coll Cardiol; 2013 Jul; 62(4):286-90. PubMed ID: 23602776
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51).
Mega JL; Braunwald E; Wiviott SD; Murphy SA; Plotnikov A; Gotcheva N; Ruda M; Gibson CM
Am J Cardiol; 2013 Aug; 112(4):472-8. PubMed ID: 23711804
[TBL] [Abstract][Full Text] [Related]
13. Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.
Turpie AG
Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):963-76. PubMed ID: 25017622
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban in patients with a recent acute coronary syndrome.
Mega JL; Braunwald E; Wiviott SD; Bassand JP; Bhatt DL; Bode C; Burton P; Cohen M; Cook-Bruns N; Fox KA; Goto S; Murphy SA; Plotnikov AN; Schneider D; Sun X; Verheugt FW; Gibson CM;
N Engl J Med; 2012 Jan; 366(1):9-19. PubMed ID: 22077192
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
MartÃnez-Rubio A; Dan GA; Kaski JC
Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Mega JL; Braunwald E; Mohanavelu S; Burton P; Poulter R; Misselwitz F; Hricak V; Barnathan ES; Bordes P; Witkowski A; Markov V; Oppenheimer L; Gibson CM;
Lancet; 2009 Jul; 374(9683):29-38. PubMed ID: 19539361
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban: a review of its use in acute coronary syndromes.
Plosker GL
Drugs; 2014 Mar; 74(4):451-64. PubMed ID: 24535922
[TBL] [Abstract][Full Text] [Related]
18. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
19. Novel direct-acting anticoagulants for risk reduction in ACS.
Dobesh PP; Oestreich JH
J Pharm Pract; 2013 Aug; 26(4):358-66. PubMed ID: 23172897
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban in the contemporary treatment of acute coronary syndromes.
Alexander D; Jeremias A
Expert Opin Investig Drugs; 2011 Jun; 20(6):849-57. PubMed ID: 21554163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
